1型血小板反应蛋白7A域在膜性肾病中的研究进展

发布时间：2018-05-27 00:11

本文选题：膜性肾病 + 特发性膜性肾病　；参考：《医学研究生学报》2017年07期

【摘要】：在PLA2R1及其抗体研究的基础上,1型血小板7A域及其抗体的发现使人们对膜性肾病又有了新的认识。THSD7A是在PLA2R1阴性的膜性肾病患者中发现的,故有部分研究报道提出PLA2R1与THSD7A的自身抗体在膜性肾病中相互排斥,但最新研究表明,THSD7A可与PLA2R1在膜性肾病患者中共存,呈现双阳性。与PLA2R1类似,THSD7A对膜性肾病具有指导诊断、治疗、监测等意义。与PLA2R1不同的是,THSD7A在人类和啮齿类动物的肾小球中均高度表达,故未来可利用小鼠模型研究THSD7A相关性膜性肾病的发病机制。文章就THSD7A及其抗体的结构、作用、与膜性肾病之间的关系及应用前景的研究进展进行综述。
[Abstract]:Based on the study of PLA2R1 and its antibody, the discovery of type 1 platelet 7A domain and its antibody makes people have a new understanding of membranous nephropathy. THSD7A is found in patients with PLA2R1 negative membranous nephropathy. Therefore, some studies have reported that autoantibodies of PLA2R1 and THSD7A repel each other in membranous nephropathy, but the latest studies show that THSD7A and PLA2R1 co-exist in patients with membranous nephropathy and present double positive. Similar to PLA2R1, THSD 7 A has guiding significance in the diagnosis, treatment and monitoring of membranous nephropathy. Different from PLA2R1, THSD7A is highly expressed in human and rodent glomeruli, so we can use mouse model to study the pathogenesis of THSD7A associated membranous nephropathy in the future. In this paper, the structure, function, relationship between THSD7A and its antibodies to membranous nephropathy and their application prospect are reviewed.
【作者单位】：南京医科大学附属无锡人民医院检验科;江苏省原子医学研究所;
【基金】：江苏省科技厅项目(BL2014022)
【分类号】：R692

【参考文献】